Cargando…
Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B mon...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/ https://www.ncbi.nlm.nih.gov/pubmed/37488838 http://dx.doi.org/10.4103/1673-5374.375299 |
_version_ | 1785101677527826432 |
---|---|
author | Alborghetti, Marika Bianchini, Edoardo De Carolis, Lanfranco Galli, Silvia Pontieri, Francesco E. Rinaldi, Domiziana |
author_facet | Alborghetti, Marika Bianchini, Edoardo De Carolis, Lanfranco Galli, Silvia Pontieri, Francesco E. Rinaldi, Domiziana |
author_sort | Alborghetti, Marika |
collection | PubMed |
description | Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson’s disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson’s disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons. Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity. Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available. The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury. The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson’s disease and beyond, focusing on possible future therapeutic applications. |
format | Online Article Text |
id | pubmed-10479837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-104798372023-09-06 Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings Alborghetti, Marika Bianchini, Edoardo De Carolis, Lanfranco Galli, Silvia Pontieri, Francesco E. Rinaldi, Domiziana Neural Regen Res Review Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson’s disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson’s disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons. Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity. Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available. The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury. The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson’s disease and beyond, focusing on possible future therapeutic applications. Wolters Kluwer - Medknow 2023-05-31 /pmc/articles/PMC10479837/ /pubmed/37488838 http://dx.doi.org/10.4103/1673-5374.375299 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Alborghetti, Marika Bianchini, Edoardo De Carolis, Lanfranco Galli, Silvia Pontieri, Francesco E. Rinaldi, Domiziana Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title | Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title_full | Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title_fullStr | Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title_full_unstemmed | Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title_short | Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
title_sort | type-b monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/ https://www.ncbi.nlm.nih.gov/pubmed/37488838 http://dx.doi.org/10.4103/1673-5374.375299 |
work_keys_str_mv | AT alborghettimarika typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings AT bianchiniedoardo typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings AT decarolislanfranco typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings AT gallisilvia typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings AT pontierifrancescoe typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings AT rinaldidomiziana typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings |